Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6.

Dickson SL, Luckman SM

Endocrinology1 Feb 1997Cited by 211 (Europe PMC)

PMID9003014DOI10.1210/endo.138.2.4907PepBankPUB-09003014

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In rats, GHRP‑6 increased the number of arcuate cells expressing c-fos mRNA compared with vehicle.
In plain wordsIn rats, GHRP‑6 increased arcuate cells expressing c-fos compared with vehicle.
Peptide
GHRP-6
Outcome
IncreaseArcuate c-fos expressing cells
Study
ratn = 10
Rat arcuate nucleus
Comparator
Vehicle
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
50 microgramsAs given in this study (rat).
Measurements
c-fos expressing cells
23 cells/section per rat
GHRP-6
c-fos expressing cells
2 cells/section per rat
vehicle
Source sentences
Summary
In GHRP-6-treated rats the mean (+/-SEM) number of cells expressing c-fos mRNA in the arcuate nucleus (23 +/- 2 cells/section per rat; n = 5) was significantly higher than for vehicle-treated controls (2 +/- 1 cells/section per rat; n = 5; P < 0.001, Mann-Whitney U test).
2 context sentences(design, population, supporting numbers)
Summary · context
Rats bearing chronically implanted jugular catheters were injected with either 50 micrograms GHRP-6 or vehicle.
Summary · context
Thirty minutes later they were terminally anesthetized and perfused with fixative.
Report a problemFND-0900301401
02AnimalAnimal study (in vivo)Mechanism
In GHRP‑6-treated rats, 51% of identifiable c-fos-expressing arcuate cells also expressed NPY mRNA.
In plain wordsIn rats given GHRP‑6, 51% of identifiable activated arcuate cells also expressed NPY messenger RNA.
Peptide
GHRP-6
Outcome
Not applicableNPY coexpression in activated cells
Study
ratn: not reported in source
Rat arcuate nucleus
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
50 microgramsAs given in this study (rat).
Measurements
NPY coexpression
51%
identifiable c-fos-expressing cells
Source sentences
Summary
Superimposed camera lucida maps indicated that, in GHRP-6-injected rats, neurochemically identifiable cells expressing c-fos mRNA also express NPY mRNA (51 +/- 4%), GRF mRNA (23 +/- 1%) tyrosine hydroxylase mRNA (11 +/- 3%), POMC mRNA (11 +/- 2%), or somatostatin mRNA (4 +/- 1%).
2 context sentences(design, population, supporting numbers)
Summary · context
Rats bearing chronically implanted jugular catheters were injected with either 50 micrograms GHRP-6 or vehicle.
Summary · context
Thirty minutes later they were terminally anesthetized and perfused with fixative.
Report a problemFND-0900301402
03AnimalAnimal study (in vivo)Mechanism
In GHRP‑6-treated rats, 23% of identifiable c-fos-expressing arcuate cells also expressed GRF mRNA.
In plain wordsIn rats given GHRP‑6, 23% of identifiable activated arcuate cells also expressed GRF messenger RNA.
Peptide
GHRP-6
Outcome
Not applicableGRF coexpression in activated cells
Study
ratn: not reported in source
Rat arcuate nucleus
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
50 microgramsAs given in this study (rat).
Measurements
GRF coexpression
23%
identifiable c-fos-expressing cells
Source sentences
Summary
Superimposed camera lucida maps indicated that, in GHRP-6-injected rats, neurochemically identifiable cells expressing c-fos mRNA also express NPY mRNA (51 +/- 4%), GRF mRNA (23 +/- 1%) tyrosine hydroxylase mRNA (11 +/- 3%), POMC mRNA (11 +/- 2%), or somatostatin mRNA (4 +/- 1%).
2 context sentences(design, population, supporting numbers)
Summary · context
Rats bearing chronically implanted jugular catheters were injected with either 50 micrograms GHRP-6 or vehicle.
Summary · context
Thirty minutes later they were terminally anesthetized and perfused with fixative.
Report a problemFND-0900301403
04AnimalAnimal study (in vivo)Mechanism
In GHRP‑6-treated rats, 11% of identifiable c-fos-expressing arcuate cells also expressed tyrosine hydroxylase mRNA.
In plain wordsIn rats given GHRP‑6, 11% of identifiable activated arcuate cells also expressed tyrosine hydroxylase messenger RNA.
Peptide
GHRP-6
Outcome
Not applicableTyrosine hydroxylase coexpression in activated cells
Study
ratn: not reported in source
Rat arcuate nucleus
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
50 microgramsAs given in this study (rat).
Measurements
Tyrosine hydroxylase coexpression
11%
identifiable c-fos-expressing cells
Source sentences
Summary
Superimposed camera lucida maps indicated that, in GHRP-6-injected rats, neurochemically identifiable cells expressing c-fos mRNA also express NPY mRNA (51 +/- 4%), GRF mRNA (23 +/- 1%) tyrosine hydroxylase mRNA (11 +/- 3%), POMC mRNA (11 +/- 2%), or somatostatin mRNA (4 +/- 1%).
2 context sentences(design, population, supporting numbers)
Summary · context
Rats bearing chronically implanted jugular catheters were injected with either 50 micrograms GHRP-6 or vehicle.
Summary · context
Thirty minutes later they were terminally anesthetized and perfused with fixative.
Report a problemFND-0900301404
05AnimalAnimal study (in vivo)Mechanism
In GHRP‑6-treated rats, 11% of identifiable c-fos-expressing arcuate cells also expressed POMC mRNA.
In plain wordsIn rats given GHRP‑6, 11% of identifiable activated arcuate cells also expressed POMC messenger RNA.
Peptide
GHRP-6
Outcome
Not applicablePOMC coexpression in activated cells
Study
ratn: not reported in source
Rat arcuate nucleus
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
50 microgramsAs given in this study (rat).
Measurements
POMC coexpression
11%
identifiable c-fos-expressing cells
Source sentences
Summary
Superimposed camera lucida maps indicated that, in GHRP-6-injected rats, neurochemically identifiable cells expressing c-fos mRNA also express NPY mRNA (51 +/- 4%), GRF mRNA (23 +/- 1%) tyrosine hydroxylase mRNA (11 +/- 3%), POMC mRNA (11 +/- 2%), or somatostatin mRNA (4 +/- 1%).
2 context sentences(design, population, supporting numbers)
Summary · context
Rats bearing chronically implanted jugular catheters were injected with either 50 micrograms GHRP-6 or vehicle.
Summary · context
Thirty minutes later they were terminally anesthetized and perfused with fixative.
Report a problemFND-0900301405
06AnimalAnimal study (in vivo)Mechanism
In GHRP‑6-treated rats, 4% of identifiable c-fos-expressing arcuate cells also expressed somatostatin mRNA.
In plain wordsIn rats given GHRP‑6, 4% of identifiable activated arcuate cells also expressed somatostatin messenger RNA.
Peptide
GHRP-6
Outcome
Not applicableSomatostatin coexpression in activated cells
Study
ratn: not reported in source
Rat arcuate nucleus
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
50 microgramsAs given in this study (rat).
Measurements
Somatostatin coexpression
4%
identifiable c-fos-expressing cells
Source sentences
Summary
Superimposed camera lucida maps indicated that, in GHRP-6-injected rats, neurochemically identifiable cells expressing c-fos mRNA also express NPY mRNA (51 +/- 4%), GRF mRNA (23 +/- 1%) tyrosine hydroxylase mRNA (11 +/- 3%), POMC mRNA (11 +/- 2%), or somatostatin mRNA (4 +/- 1%).
2 context sentences(design, population, supporting numbers)
Summary · context
Rats bearing chronically implanted jugular catheters were injected with either 50 micrograms GHRP-6 or vehicle.
Summary · context
Thirty minutes later they were terminally anesthetized and perfused with fixative.
Report a problemFND-0900301406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.